Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Miki Fukutani
Observed name:
M. Fukutani
Institution:
National Cancer Center Hospital East
Observed institutions:
National Cancer Centre Japan,
Hiroshima University Hospital,
National Cancer Center Hospital East,
National Cancer Center Exploratory Oncology Research & Clinical Trial Center,
Kitasato University
ORCID:
0009-0000-1484-8393
Observed ORCID:
0009-0000-1484-8393
OpenAlex ID:
A5062104528
Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)
2016
·
Kohei Shitara
, Toshihiko Doi
, et al.
·
Gastric Cancer
·
115
PDF
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
2021
·
Akihito Kawazoe
, Kota Itahashi
, et al.
·
Clinical Cancer Research
·
75
Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)
2017
·
Kohei Shitara
, Toshihiko Doi
, et al.
·
Gastric Cancer
·
70
PDF
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
2020
·
Hideaki Bando
, Daisuke Kotani
, et al.
·
BMC Cancer
·
64
PDF
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).
2023
·
Keiju Aokage
, Yoshihisa Shimada
, et al.
·
Journal of Clinical Oncology
·
21
Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer
2024
·
Takeshi Masuda
, Taizo Hirata
, et al.
·
Journal of Thoracic Disease
·
17
Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer
2011
·
Takafumi Toita
, Shingo Kato
, et al.
·
International Journal of Clinical Oncology
·
17
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
2024
·
Keiju Aokage
, Shohei Koyama
, et al.
·
Clinical Cancer Research
·
16
TRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602)
2017
·
Y. Nakamura
, W. Okamoto
, et al.
·
Annals of Oncology
·
14
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)
2020
·
Akihito Kawazoe
, Daisuke Takahari
, et al.
·
Gastric Cancer
·
13
PDF
Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial
2019
·
Yu Akazawa
, Ako Hosono
, et al.
·
Cancer Science
·
13
PDF
An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).
2015
·
Yasutoshi Kuboki
, Tomohiro Nishina
, et al.
·
Journal of Clinical Oncology
·
11
Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer
2022
·
Keiju Aokage
, Masahiro Tsuboi
, et al.
·
Japanese Journal of Clinical Oncology
·
10
A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)
2025
·
Tomohiro Kadota
, Rika Fujii
, et al.
·
Gastric Cancer
·
8
Abstract 5185: First in human trial of off-the shelf iPS derived anti-GPC3 NK cells for recurrent ovarian clear cell carcinoma with peritoneal dissemination
2022
·
Kenichi Harano
, Shin Kaneko
, et al.
·
Cancer Research
·
6
TAS-116, an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
2020
·
Akihito Kawazoe
, Noboru Yamamoto
, et al.
·
Journal of Clinical Oncology
·
5
A phase Ib study of near infrared photoimmunotherapy (NIR-PIT) using ASP-1929 in combination with nivolumab and for patients with advanced gastric or esophageal cancer (GE-PIT study, EPOC1901).
2020
·
Tomohiro Kadota
, Daisuke Kotani
, et al.
·
Journal of Clinical Oncology
·
5
Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST).
2020
·
Tsuyoshi Takahashi
, Toshirou Nishida
, et al.
·
Journal of Clinical Oncology
·
4
bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).
2019
·
Yoshiaki Nakamura
, Yoshito Komatsu
, et al.
·
Journal of Clinical Oncology
·
3
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
2017
·
Yasutoshi Kuboki
, Akihito Kawazoe
, et al.
·
Journal of Clinical Oncology
·
3
TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.
2019
·
Hideaki Bando
, Daisuke Kotani
, et al.
·
Journal of Clinical Oncology
·
2
Abstract 1211: Biomarker analysis of pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer: EAST ENERGY trial
2024
·
Kotaro Nomura
, Shogo Kumagai
, et al.
·
Cancer Research
·
1
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
2019
·
D. Takahari
, A. Kawazoe
, et al.
·
Annals of Oncology
·
1
Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study
2019
·
Yoichi Naito
, Toshihiko Doi
, et al.
·
Annals of Oncology
·
1
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
2016
·
Yasutoshi Kuboki
, Tomohiro Nishina
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
55
Citation count:
496
H-index:
11
I10-index:
13
Year
Topic
Type